Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Moderate Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $23.00.

ZVRA has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, April 11th. Weiss Ratings raised shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, March 10th. BTIG Research initiated coverage on shares of Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 price target for the company. Guggenheim set a $23.00 price target on shares of Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, HC Wainwright set a $26.00 price target on shares of Zevra Therapeutics in a report on Tuesday, December 30th.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, insider Adrian W. Quartel sold 4,533 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a total value of $40,026.39. Following the completion of the transaction, the insider owned 9,723 shares of the company’s stock, valued at approximately $85,854.09. This trade represents a 31.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Neil F. Mcfarlane sold 91,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the completion of the transaction, the chief executive officer directly owned 364,350 shares of the company’s stock, valued at approximately $3,417,603. This represents a 19.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 114,158 shares of company stock worth $1,062,878. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in shares of Zevra Therapeutics during the fourth quarter worth $53,000. DGS Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the fourth quarter worth $133,000. Millennium Management LLC raised its holdings in shares of Zevra Therapeutics by 9.6% during the fourth quarter. Millennium Management LLC now owns 1,134,358 shares of the company’s stock worth $10,164,000 after purchasing an additional 99,107 shares during the last quarter. Man Group plc raised its holdings in shares of Zevra Therapeutics by 174.4% during the fourth quarter. Man Group plc now owns 92,347 shares of the company’s stock worth $827,000 after purchasing an additional 58,695 shares during the last quarter. Finally, Engineers Gate Manager LP raised its holdings in shares of Zevra Therapeutics by 23.4% during the fourth quarter. Engineers Gate Manager LP now owns 44,020 shares of the company’s stock worth $394,000 after purchasing an additional 8,359 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $10.78 on Thursday. The company has a market cap of $632.89 million, a price-to-earnings ratio of 8.11 and a beta of 0.89. Zevra Therapeutics has a twelve month low of $6.85 and a twelve month high of $13.16. The company has a quick ratio of 5.63, a current ratio of 5.68 and a debt-to-equity ratio of 0.40. The company has a 50 day moving average of $9.36 and a two-hundred day moving average of $9.28.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.